华兰疫苗跌2.92% 2022年上市见顶募22.76亿元

Group 1 - The core viewpoint of the news is that Hualan Vaccine's stock is currently in a state of decline, having dropped to 20.62 yuan, reflecting a decrease of 2.92% [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext board on February 18, 2022, with an initial public offering (IPO) price of 56.88 yuan per share and a total of 40.01 million shares issued [1][2] - On its first trading day, Hualan Vaccine reached a peak price of 79.78 yuan, indicating strong initial market interest [2] Group 2 - The total amount raised from the IPO was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [2] - The funds raised were intended for various projects, including the development and industrialization of flu vaccines, rabies vaccines, multi-component bacterial vaccines, and new pneumonia vaccines, as well as the establishment of a new vaccine research platform [2] - The total issuance costs for the IPO amounted to 31.5657 million yuan, with the lead underwriter, Huatai United Securities, receiving a total of 22 million yuan in underwriting and sponsorship fees [2] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]